A multicomponent intervention incorporating CYP2C19 genotype-guided therapy and integrated pharmaceutical care reduces hospitalizations and improves adherence in ischemic stroke
A multicomponent intervention comprising CYP2C19 genotype-guided therapy and intensive pharmacist-led integrated pharmaceutical care significantly improved medication adherence and reduced hospitalization frequency, with more pronounced benefits observed in patients at high risk of stroke recurrence, without increasing...